<DOC>
<DOCNO>EP-0620824</DOCNO> 
<TEXT>
<INVENTION-TITLE>
PEPTIDES WITH TACHYKININ ANTAGONIST ACTIVITY.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3140	A61K3140	A61K314015	A61K314015	A61K314025	A61K314025	A61K3144	A61K3144	A61K314427	A61K314427	A61K31443	A61K3800	A61K3800	A61P3700	A61P3700	C07D20700	C07D207273	C07D20734	C07D40100	C07D40112	C07D40300	C07D40312	C07D40500	C07D40512	C07K100	C07K1113	C07K500	C07K502	C07K5078	C07K5097	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07K	C07K	C07K	C07K	C07K	C07K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K38	A61K38	A61P37	A61P37	C07D207	C07D207	C07D207	C07D401	C07D401	C07D403	C07D403	C07D405	C07D405	C07K1	C07K1	C07K5	C07K5	C07K5	C07K5	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The compound of formula (I) which is useful for treating or preventing Tachykinin-mediated diseases.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
FUJISAWA PHARMACEUTICAL CO
</APPLICANT-NAME>
<APPLICANT-NAME>
FUJISAWA PHARMACEUTICAL CO., LTD.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
HAGIWARA DAIJIRO
</INVENTOR-NAME>
<INVENTOR-NAME>
IGARI NORIHIRO
</INVENTOR-NAME>
<INVENTOR-NAME>
MATSUO MASAAKI
</INVENTOR-NAME>
<INVENTOR-NAME>
MIYAKE HIROISHI
</INVENTOR-NAME>
<INVENTOR-NAME>
MURANO KENJI
</INVENTOR-NAME>
<INVENTOR-NAME>
HAGIWARA, DAIJIRO
</INVENTOR-NAME>
<INVENTOR-NAME>
IGARI, NORIHIRO
</INVENTOR-NAME>
<INVENTOR-NAME>
MATSUO, MASAAKI
</INVENTOR-NAME>
<INVENTOR-NAME>
MIYAKE, HIROISHI
</INVENTOR-NAME>
<INVENTOR-NAME>
MURANO, KENJI
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
 DESCRIPTIONPEPTIDES WITH TACHYKININ ANTAGONIST ACTIVITYTechnical FieldThe present invention relates to new peptide compound and a pharmaceutically acceptable salt thereof.More particularly, it relates to new peptide compound and a pharmaceutically acceptable salt thereof which have pharmacological activities such as Tachykinin antagonism, especially Substance P antagonism, Neurokinin A antagonism, Neurokinin B antagonism, and the like, to a process for preparation thereof, to a pharmaceutical composition comprising the same, and to a use of the same as a medicament.Disclosure of the InventionAccordingly, one object of the present invention is to provide new and useful peptide compound and a pharmaceutically acceptable salt thereof which have pharmacological activities such as Tachykinin antagonism, especially Substance P antagonism, Neurokinin A antagonism, Neurokinin B antagonism, and the like.Another object of the present invention is to provide a process for the preparation of said peptide compound and a salt thereof.A further object of the present invention is to provide a pharmaceutical composition comprising, as an active ingredient, said peptide compound and a pharmaceutically acceptable salt thereof.Still further object of the present invention is to provide a use of said peptide compound or a pharmaceutically acceptable salt thereof as Tachykinin antagonist, especially Substance P antagonist, Neurokinin A antagonist or Neurokinin B antagonist, useful for 

 treating or preventing Tachykinin-mediated diseases, for example, respiratory diseases such as asthma, bronchitis, rhinitis, cough, expectoration, and the like; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis, and the like; inflammatory diseases such as rheumatoid arthritis, osteoarthritis, and the like; pains or aches (e.g., migraine, headache, toothache, cancerous pain, back pain, etc.); and the like in human being or animals.The object compound of the present invention can be represented by the following general formula (I) .wherein R1 is aryl, pyridyl, pyrrolyl, or a group of the formula :wherein the line and the dotted line are a single bond or a double bond, X is CH or N and Z is -0-, -S- or -NH-, each of which may have suitable substituent(s);2 R is ar(lower)alkyl which may have suitable substituent(s) ;R3 is lower alkyl which may have suitable 

 substituent(s) ;R ,4 is ar(lower)alkyl which
</DESCRIPTION>
<CLAIMS>
 - 50 -
CLAIMS
A compound of the formula:
O
wherein R is aryl, pyridyl, pyrrolyl, or a group of the formula
wherein the line and the dotted line are a single bond or a double bond,
X is CH or N and Z is -0-, -S- or -NH-, each of which may have suitable substituent(s) ; 2 R is ar(lower)alkyl which may have suitable substituent(s) ;
R is lloowweerr aallkkyyll wwhhiiich may have suitable substituent(s) ; R is aarr((lloowweerr))aallkkyyll 
<
which may have suitable substituent(s) ; 6
R is hydrogen or lower alkyl;
A is bond, lower alkylene or lower alkenylene;
7 7
Y is 0 or N-R m which R is hydrogen or lower alkyl; m i •s 
n
0 or ,1; and 


 n is an integer of 0 to 2, or a pharmaceutically acceptable salt thereof.
A compound of claim 1, wherein
R is Cg-C--. aryl, pyridyl, pyrrolyl, or a group of the formula :
in which Z is -N- or -0-, wherein i
»
R is hydrogen; lower alkyl; di(lower)alkylamino(lower)alkyl; amino(lower)alkyl; acylamino(lower)alkyl; cyano(lower)alkyl; amidino(lower)alkyl; guanidino(lower)alkyl;
[2-lower alkyl-3-cyanoisothioureido]
(lower)alkyl; or
[3-lower alkyl-2-cyanoguanidino]-
(lower)alkyl; 2 R is Cg-C,
0
 ar(lower)alkyl;
R is lower alkyl;
4 R is Cg-C
10
 ar(lower)alkyl;
R is hydrogen or lower alkyl;
A is bond or lower alkenylene; Y is O or N-R 7 i.n which R7 iiss 
'
hydrogen or lower alkyl; is 0 to 1; and n is an integer of 1 


 A compound of claim 2, wherein
R 
"
 is pphheennyyll,, pyridyl, pyrrolyl, or a group of the formula
in which Z is -N- or -0-, wherein
R is hydrogen; lower alkyl; di(lower)alkylamino(lower)alkyl; amino(lower)alkyl; lower alkoxycarbonylamino(lower)alkyl; cyano(lower)alkyl; amidino(lower)alkyl; guanidino(lower)alkyl;
[2-lower alkyl-3-cyanoisothioureido]-
(lower)alkyl; or
[3-lower alkyl-2-cyanoguanidino]-
(lower)alkyl;
2 R s phenyl(lower)alkyl, mono or di(lower)alkyl- phenyKlower)alkyl, naphthyl(lower) lkyl; and R is phenyl(lower)alkyl.
A process for preparing a compound (I) , or a salt thereof which comprises
(1) reacting a compound of the formula:

 wherein R
ώ
, R , R , R and n are each as defined above, or its reactive derivative at the amino group, or a salt thereof, with a compound of the formula:
R -A-COOH (III)
wherein R and A are each as defined above, or its reactive derivative at the carboxy group, or a salt thereof, to give a compound of the formula :
wherein R 1, R2, R3, R4, R6, A and n are each as defined above, or a salt thereof, or
(2) subjecting a compound of the formula
wherein R , R , R , R , A, X, Y, m and n are each as defined above, or a salt thereof, to addition reaction of cyano- (lower)alkene, to give a compound of the formula : 

wherein R , R , R , R , A, X, Y, m and n are each as defined above, and
R ,5 i.s cyano(lower)alkyl, or a salt thereof, or
(3) reacting the compound (ϊ-c) or a slat thereof with ammonia or a salt thereof to give a compound of the formula :
wherein R , R , R , R , A, X, Y, m and n are each as defined above, and 5 R, is amidino(lower)alkyl, or a salt thereof, or
(4) subjecting a compound of the formula :
wherein R , R , R , R , A, X, Y, m and n are each 


 as defined above, and
R ,
r
5 is protected amino(lower)alkyl, or a salt thereof, to removal reaction of the
5 amino-protective group in R , to give a compound of the formula :
wherein R , R , R , R , A, X, Y, m and n are each as defined above, and R, is amino(lower)alkyl, or a salt thereof, or
(5) reacting the compound (I-f) or a salt thereof with a compound of the formula :
L-R
c
 (IV)
wherein R
a
 is amidino or (lower)alkylthio)- (cyanoimino)methyl, and L is a leaving group, to give a compound of the formula :
wherein R , R , R , R , A, X, Y, m and n are each as defined above, and 


 R
D
 is guanidino(lower)alkyl or [2-lower alkyl-3- cyanoisothioureido] (lower)alkyl, or a salt thereof, or
(6) reacting a compound of the formula :
wherein R , R , R , R , A, X, Y, m and n are each as defined above, and R
f
 is [2-lower alkyl-3-cyanoisothioureido]- (lower)alkyl, or a salt thereof, with lower alkylamine, to give a compound of the formula :
wherein R , R , R , R , A, X, Y, m and n are each as defined above, and
R is [3-lower alkyl-2-cyanoguanidino]- y
(lower)alkyl, or a salt thereof.
(7) reacting the compound (I-a) or a salt thereof, with compound of the formula (V) : 


 R
7
NH, (V)
7 wherein R is hydrogen or lower alkyl, or a salt thereof, to give a compound of the formula
wherein R 1, R2, R3, R4, R6, R7, A, and n are each as defined above, or a salt thereof, or
(8) subjecting the compound (II) or its reactive derivative at the amino group, or a salt thereof, to Mannich reaction, to give a compound of the formula :
wherein R , R , R , R , R and n are each as defined above, or a salt thereof.
A pharmaceutical composition comprising a compound of claim 1 or pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient. 
•

6. A method or treating or preventing Tachykinin-mediated diseases, which comprises administering a compound of claim 1 or pharmaceutically acceptable salt there of to human being or animals.
7. Use of a compound of claim 1 or pharmaceutically acceptable salt thereof as a medicament.
8. Use of compound of claim 1 or pharmaceutically acceptable salt thereof as Tachykinin antagonist.
9. A process for preparing a pharmaceutical composition which comprises admixing a compound of claim 1 or pharmaceutically acceptable salt thereof with a pharmaceutically acceptable, substantially non-toxic carrier or excipient. 

</CLAIMS>
</TEXT>
</DOC>
